Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia

American Journal of Health-System Pharmacy

Volumn 62, Issue 23, 2005, Pages 2491-2494

  Plakogiannis, Roda ^a,b   Cohen, Henry ^a,c   Taft, David ^a  

^a LONG ISLAND UNIVERSITY   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c KINGSBROOK JEWISH MEDICAL CENTER   (United States)

Author keywords

Antilipemic agents; Atorvastatin calcium; Circadian rhythm; Dosage schedules; Half life; Hyperlipidemia; Pharmacokinetics

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHARMACIST; PRIORITY JOURNAL; TEACHING HOSPITAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 28344442939     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050072     Document Type: Article

References (23)

1. Hardman JG, Limbird LE, Gilman AG. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Health Professional; 2001:971-1002.
2. Lipitor (atorvastatin calcium) package insert. Morris Plains, NJ: Pfizer Pharmaceuticals; 2003.
3. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995; 15:678-82.
4. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81:582-7.
5. Schoepp J. How does atorvastatin compare to other HMG-CoA reductase inhibitors? Pharm Pract Can. 1997; 79:35-6.
6. Wierzbicki AS, Lumb PJ, Chik G et al. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol. 2000; 86:547-9.
7. Bertolini S, Bittolo GB, Campbell LM et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997; 130:191-7.
8. Davidson M, McKenney J, Stein E et al. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997; 79:1475-81.
9. Parker TS, McNamara DJ, Brown C et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci. 1982; 79:3037-41.
10. Mevacor (lovastatin) package insert. Whitehouse Station, NJ: Merck Pharmaceuticals; 2004.
11. Lescol (fluvastatin) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2004.
12. Pravachol (pravastatin) package insert. Princeton, NJ: Bristol-Myers Squibb; 2003.
13. Zocor (simvastatin) package insert. Whitehouse Station, NJ: Merck Pharmaceuticals; 2004.
14. Crestor (rosuvastatin) package insert. Wilmington, DE: AstraZeneca; 2003.
15. Illingworth RD. Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther. 1986; 40:338-43.
16. Saito Y, Yoshida S, Nakaya N et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb. 1991; 11:816-26.
17. Hunninghake DB, Mellies MJ, Goldberg AC et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Atherosclerosis. 1990; 85:219-27.
18. Cilla DD Jr, Gibson DM, Whitfield LR et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996; 36:604-9.
19. Insull W Jr, Black D, Dujovne C et al. Efficacy and safety of once-daily vs twice-daily dosing fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med. 1994; 154:2449-55.
20. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002; 54:472-7.
21. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994; 89:1333-445.
22. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
23. Erratum, Circulation. 2004; 110:763.